share_log

Fujian Aonong Biological Technology Group Incorporation Limited's (SHSE:603363) Market Cap Surged CN¥374m Last Week, Retail Investors Who Have a Lot Riding on the Company Were Rewarded

Fujian Aonong Biological Technology Group Incorporation Limited's (SHSE:603363) Market Cap Surged CN¥374m Last Week, Retail Investors Who Have a Lot Riding on the Company Were Rewarded

上週,傲農生物(SHSE:603363)市值猛增3.74億元人民幣,對該公司寄予厚望的散戶投資者受到了回報。
Simply Wall St ·  06/17 20:27

Key Insights

主要見解

  • The considerable ownership by retail investors in Fujian Aonong Biological Technology Group Incorporation indicates that they collectively have a greater say in management and business strategy
  • The top 5 shareholders own 52% of the company
  • Insider ownership in Fujian Aonong Biological Technology Group Incorporation is 13%
  • 福建傲農生物技術集團股份有限公司中零售投資者的相當大的持股,表明他們在管理和業務策略方面有更大的發言權。
  • 前五大股東持有該公司52%的股份。
  • 福建傲農生物技術集團股份有限公司中內部股權比例爲13%。

If you want to know who really controls Fujian Aonong Biological Technology Group Incorporation Limited (SHSE:603363), then you'll have to look at the makeup of its share registry. We can see that retail investors own the lion's share in the company with 41% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

如果你想知道福建傲農生物技術集團股份有限公司(SHSE: 603363)到底由誰控制,那麼你需要看看它的股權登記簿的組成。我們可以看到,零售投資者擁有該公司41%的股權。亦即,如果股票上漲,則該團體將獲得最大的利益(或者如果出現下行趨勢,則遭受最大的損失)。

Clearly, retail investors benefitted the most after the company's market cap rose by CN¥374m last week.

顯然,上週該公司的市值上漲了37400萬人民幣,使得零售投資者獲益最大。

In the chart below, we zoom in on the different ownership groups of Fujian Aonong Biological Technology Group Incorporation.

下面的圖表展示了福建傲農生物技術集團股份有限公司不同的股權擁有者。

ownership-breakdown
SHSE:603363 Ownership Breakdown June 18th 2024
SHSE:603363 2024年6月18日股權份額分佈

What Does The Institutional Ownership Tell Us About Fujian Aonong Biological Technology Group Incorporation?

福建傲農生物技術集團股份有限公司機構投資者的情況如何?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

機構通常在向自己的投資者報告時會針對一個基準進行衡量,因此一旦某隻股票被納入主要指數,他們通常會更加熱衷於該股票。我們預計大多數公司都會有一些機構在登記簿上,尤其是那些正在增長的公司。

We can see that Fujian Aonong Biological Technology Group Incorporation does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Fujian Aonong Biological Technology Group Incorporation's earnings history below. Of course, the future is what really matters.

我們可以看到,福建傲農生物技術集團股份有限公司確實擁有機構投資者;而且它們持有公司股票的很大一部分。這意味着那些機構的分析師已經研究過這支股票並且看好。但是,他們也可能像別人一樣錯了。如果多家機構同時改變對一支股票的看法,股價可能會迅速下跌。因此,值得關注的是福建傲農生物技術集團股份有限公司以下的盈利歷史。當然,未來才是真正重要的。

earnings-and-revenue-growth
SHSE:603363 Earnings and Revenue Growth June 18th 2024
SHSE:603363 2024年6月18日的盈利和營業收入增長情況

Fujian Aonong Biological Technology Group Incorporation is not owned by hedge funds. Xiamen Aonong Investment Co., Ltd. is currently the largest shareholder, with 31% of shares outstanding. You Lin Wu is the second largest shareholder owning 10% of common stock, and Zhangzhou Financial Investment Group Co., Ltd. holds about 5.1% of the company stock. You Lin Wu, who is the second-largest shareholder, also happens to hold the title of Chief Executive Officer.

福建傲農生物技術集團股份有限公司不是由對沖基金持有,廈門傲農投資有限公司目前是該公司流通股中最大的股東,持股31%。遊林武是第二大股東,持有普通股的10%,漳州金融投資集團有限公司持有該公司股份的約5.1%。遊林武是第二大股東,同時也是首席執行官。

On looking further, we found that 52% of the shares are owned by the top 5 shareholders. In other words, these shareholders have a meaningful say in the decisions of the company.

進一步了解後,我們發現52%的股份由前5名股東持有。 換句話說,這些股東對公司的決策有相當大的影響。

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

儘管有必要研究公司的機構持股數據,但研究分析師的情緒也是有道理的,以了解風向。這隻股票有一些分析師的覆蓋,但不多。因此,有提高更多的分析涵蓋面的空間。

Insider Ownership Of Fujian Aonong Biological Technology Group Incorporation

福建傲農生物技術集團股份有限公司內部股權比例

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

雖然內部人員的具體定義可能是主觀的,但幾乎所有人都認爲董事會成員是內部人員。公司管理層應向董事會回答問題,後者應代表股東的利益。值得注意的是,有時高層管理人員也會成爲董事會成員。

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

當內部人持股情況表明領導層思考和公司真正所有者一樣時,內部所有權是積極的。然而,高達內部人士所有權也可能爲公司內的小團體帶來巨大的權力。在某些情況下,這可能是負面的。

Our most recent data indicates that insiders own a reasonable proportion of Fujian Aonong Biological Technology Group Incorporation Limited. Insiders own CN¥498m worth of shares in the CN¥3.8b company. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling.

我們最新的數據表明,福建傲農生物技術集團股份有限公司的內部股權比例相當大。內部人擁有價值49800萬元人民幣的股票,佔該38億元公司的比例。這可能表明創始人仍然擁有很多股票。您可以在此處單擊以查看他們是否一直在買賣。

General Public Ownership

一般大衆所有權

The general public-- including retail investors -- own 41% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

普通公衆——包括散戶投資者——持有該公司41%的股份,因此,他們不容易被忽視。儘管這個集團不能稱霸,但它肯定能對公司的經營方式產生真正的影響。

Private Company Ownership

私有公司的所有權

We can see that Private Companies own 40%, of the shares on issue. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

我們可以看到,私人公司擁有已發行股份的40%。深入了解這一點可能會非常有價值。例如,如果相關方,如內部人員,對這些私人企業之一有利害關係,那麼應該在年度報告中披露。私人公司也可能對該公司具有戰略利益。

Next Steps:

下一步:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Fujian Aonong Biological Technology Group Incorporation , and understanding them should be part of your investment process.

雖然考慮擁有公司的不同團體值得一試,但更重要的因素是投資風險的持續存在。我們已經確定了福建傲農生物技術集團股份有限公司的兩個警示標誌,理解它們應該是您的投資過程的一部分。

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

最終,未來最重要。您可以在這份關於該公司分析師預測的免費報告中獲取有關信息。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者發送電子郵件至editorial-team@simplywallst.com。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論